{
    "nct_id": "NCT03199274",
    "official_title": "Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma",
    "inclusion_criteria": "* Be scheduled for sub-lobar radioembolization therapy of a previously untreated HCC mass < 6 cm visible on grayscale ultrasound\n* Be medically stable\n* If a female of child-bearing age, have a negative pregnancy test prior to each ultrasound exam\n* Have signed informed consent to participate in the study\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Females who are pregnant or nursing\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable; for example:\n\n  * Patients on life support or in a critical care unit\n  * Patients with unstable occlusive disease (e.g., crescendo angina)\n  * Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia\n  * Patients with uncontrolled congestive heart failure (New York heart Association [NYHA] class IV)\n* Patients with recent cerebral hemorrhage\n* Patients with known sensitivities to albumin, blood, or blood products\n* Patients with known hypersensitivity to perflutren\n* Patients with known cardiac shunts\n* Patients with known congenital heart defects\n* Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary embolism\n* Patients with respiratory distress syndrome\n* Patients with a history of bleeding disorders\n* Patients with bilirubin levels > 2 mg/dL",
    "miscellaneous_criteria": ""
}